Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor X a inhibitor, in healthy subjects

Cited by (285)

Items 101–200 of 285

1. Apixaban: A Review in Venous Thromboembolism
   Sarah L. Greig, Karly P. Garnock-Jones · 2016 · Drugs
2. The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
   Charles E. Frost, Yan Jun Song, Zhigang Yu, Jessie J.J. Wang, Lois Lee, Alan E. Schuster, Allyson Pollack, Frank P. LaCreta · 2017 · Clinical Pharmacology Advances and Applications
3. Management of Venous Thromboembolism
   Shannon W. Finks, Toby C. Trujillo, Paul P. Dobesh · 2016 · Annals of Pharmacotherapy
4. Evaluation of the Effect of Apixaban on INR in the Inpatient Population
   Mary P. Kovacevic, Kenneth E. Lupi, Adrian Wong, James F. Gilmore, Rhynn J. Malloy · 2019 · Journal of Cardiovascular Pharmacology and Therapeutics
5. Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition
   Jasleen K. Sodhi, Shuaibing Liu, Leslie Z. Benet · 2020 · Pharmaceutical Research
6. Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects
   Charles E. Frost, Andrew Shenker, Stanford S. Jhee, Zhigang Yu, Jessie J.J. Wang, Alexander Bragat, Janice M. Pursley, Frank P. LaCreta · 2018 · Clinical Pharmacology Advances and Applications
7. Off-label use of reduced dose direct oral factor Xa inhibitors in subjects with atrial fibrillation: a review of clinical evidence
   Mario Bo, Alberto Corsini, Enrico Brunetti, Giancarlo Isaia, Maddalena Gibello, Nicola Ferri, Daniela Poli, Niccolò Marchionni, Gaetano Maria De Ferrari · 2020 · European Heart Journal - Cardiovascular Pharmacotherapy
8. Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review
   Angela Elma Edwina, Nada Dia, Erwin Dreesen, Thomas Vanassche, Peter B. Verhamme, Isabel Spriet, Lorenz Roger Van der Linden, Jos Tournoy · 2023 · Clinical Pharmacokinetics
9. Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation
   Lluis Pujadas-Mestres, Irene López-Vílchez, Eduardo Arellano‐Rodrigo, Joan Carles Reverter, Antonio José López-Farré, Maribel Díaz‐Ricart, Juan J. Badimón, Ginés Escolar · 2017 · PLoS ONE
10. A comprehensive evaluation of apixaban in the treatment of venous thromboembolism
    Jennifer L. Koehl, Bryan D. Hayes, Hanny T. Al-Samkari, Rachel Pam Greenerger Rosovsky · 2020 · Expert Review of Hematology
11. Green fitted second derivative synchronous spectrofluorometric method for simultaneous determination of remdesivir and apixaban at Nano gram scale in the spiked human plasma
    Afnan S. Batubara, Ahmed H. Abdelazim, Mohammed Gamal, Ahmed A. Almrasy, Sherif Ramzy · 2022 · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy
12. Emergent Bleeding in Patients Receiving Direct Oral Anticoagulants
    Richard L. Summers, Sarah A. Sterling · 2016 · Air Medical Journal
13. Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways
    Andrea Huppertz, Caspar Grond‐Ginsbach, Chris Dumschat, Kathrin Isabelle Foerster, Jürgen Burhenne, Johanna Weiß, David Czock, Jan Christoph Purrucker, Timolaos Rizos, Walter E. Haefeli · 2019 · BMC Pharmacology and Toxicology
14. Stroke and Bleeding Risks in Patients with Atrial Fibrillation Treated with Reduced Apixaban Dose: A Real‐Life Study
    Maram Salameh, Naomi Gronich, Nili Stein, Antonio Kotler, Gad Rennert, Eitan Auriel, Walid Saliba · 2020 · Clinical Pharmacology & Therapeutics
15. The value and limitations of new oral anticoagulant plasma level assessments
    Lorenz Roger Van der Linden, Julie Hias, Thomas Vanassche · 2022 · European Heart Journal Supplements
16. How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study
    Armando Tripodi, Lidia Padovan, Sophie Testa, Cristina Legnani, Veena Chantarangkul, Erica Scalambrino, Silvia Ludovici, Laura Bassi, Flora Peyvandi · 2014 · Clinical Chemistry and Laboratory Medicine (CCLM)
17. Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer
    Hiroki A. Ueyama, Hirotaka Miyashita, Hisato Takagi, Christina Cruz, Alfred Burger, Αlexandros Briasoulis, Toshiki Kuno · 2020 · Journal of Thrombosis and Thrombolysis
18. Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol
    Jessica Kepplinger, Alexandra Prakapenia, Kristian Barlinn, Gabriele Siegert, Siegmund Gehrisch, Charlotte Zerna, Jan Beyer‐Westendorf, Volker Puetz, Heinz Reichmann, Timo Siepmann et al. · 2015 · Journal of Thrombosis and Thrombolysis
19. Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
    Charles E. Frost, Van T. Ly, Samira J. Merali · 2021 · Drugs in R&D
20. Real world prescribing practices of apixaban or rivaroxaban lead-in doses for the treatment of venous thromboembolism in hospitalized patients
    Matthew Adam Williams, Tania Ahuja, Veronica Raco, John Papadopoulos, David Green, Eugene Yuriditsky, Serena Arnouk · 2022 · Journal of Thrombosis and Thrombolysis
21. Apixaban: A Review of its Use for Reducing the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation
    Gillian M. Keating · 2013 · Drugs
22. Monitoring DOACs with a Novel Dielectric Microsensor: A Clinical Study
    Debnath Maji, Aman Opneja, Michael A. Suster, Kara L. Bane, Brigid M. Wilson, Pedram Mohseni, Evi X. Stavrou · 2020 · Thrombosis and Haemostasis
23. Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation
    Ran Nissan, Galia Spectre, Avital Hershkovitz, Hefziba Green, Shai O. Shimony, Lisa Cooper, Sigal Nakav, Tzippy Shochat, Alon Grossman, Shmuel Fuchs · 2018 · Drugs & Aging
24. Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion
    Sara Zochert, Kiara M Oltman, Brittany M Elgersma, Thaddaus R. Hellwig, Michael P. Gulseth · 2019 · American Journal of Health-System Pharmacy
25. Initial apixaban dosing in patients with atrial fibrillation
    Alexander Buchholz, Laura Ueberham, Kaja Gorczynska, Borislav Dinov, Sebastian Hilbert, Nikolaos Dagres, Daniela Husser, Gerhard Hindricks, Andreas Bollmann · 2018 · Clinical Cardiology
26. Monitoring anticoagulant therapy with new oral agents
    Allan Ramos-Esquivel · 2015 · World Journal of Methodology
27. A level‐headed approach to measuring direct oral anticoagulants: A 2‐year retrospective analysis of DOAC levels from a tertiary UK centre
    Nicholas Denny, Lynne Keighley, Zubin Siganporia, Jecko V. Thachil, Michael J. Nash · 2018 · International Journal of Laboratory Hematology
28. Apixaban Single‐Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration
    Charles E. Frost, Samira J. Merali, Andrew Shenker, Yu Chen Barrett, Frank P. LaCreta · 2021 · Clinical Pharmacology in Drug Development
29. Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban
    David A. Bookstaver, Kimberly S. Sparks, Brandon S. Pybus, Dustin K. Davis, Sean R. Marcsisin, Jason C. Sousa · 2017 · Annals of Pharmacotherapy
30. Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study
    Ines Van den bosch, Thomas W. Bouillon, Peter B. Verhamme, Thomas Vanassche, Marc G Jacquemin, Maarten Coemans, Dirk R. J. Kuypers, Björn K.I. Meijers · 2020 · Nephrology Dialysis Transplantation
31. Direct oral anticoagulants (DOACs) and neck of femur fractures: Standardising the perioperative management and time to surgery
    Rohi Shah, Nomaan Sheikh, Jitendra Mangwani, N. J. Morgan, Hamidreza Khairandish · 2020 · Journal of Clinical Orthopaedics and Trauma
32. Comparative efficacy and safety of oral anticoagulants for the treatment of venous thromboembolism in the patients with different renal functions: a systematic review, pairwise and network meta-analysis
    Xiaole Su, Bingjuan Yan, Lihua Wang, Hong Cheng, Yipu Chen · 2022 · BMJ Open
33. Evaluation of the Antithrombotic Effects of Rivaroxaban and Apixaban Using the Total Thrombus-Formation Analysis System®: In Vitro and Ex Vivo Studies
    Hidekazu Sugihara, Yoshiaki Idemoto, Takashi Kuwano, Yoshihisa Nagata, Joji Morii, Makoto Sugihara, Masahiro Ogawa, Shin‐ichiro Miura, Keijiro Saku · 2016 · Journal of Clinical Medicine Research
34. Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients
    Hideki Yoshioka, Hiromi Sato, Hiroto Hatakeyama, Akihiro Hisaka · 2018 · Blood Advances
35. Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization
    Tigran Khachatryan, Christopher Hauschild, Jason Hoff, Tahmeed A. Contractor, Arthur Khachatryan, Huyentran N Tran, Bert Matsuo, Alan K. Jacobson, Anthony A. Hilliard · 2019 · American Journal of Cardiovascular Drugs
36. Laboratory assessment of the direct oral anticoagulants: who can benefit?
    Imo J. Akpan, Adam C. Cuker · 2021 · Kardiologia Polska
37. Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism
    Xianchen Liu, John Russell Thompson, Hemant M. Phatak, Jack Mardekian, Anthony R. Porcari, Margot R. Johnson, Alexander Thomas Cohen · 2015 · Thrombosis and Haemostasis
38. Non-vitamin K Antagonist Oral Anticoagulants (NOACs): a View from the Laboratory
    Andrew D. Blann · 2014 · British Journal of Biomedical Science
39. Overview of direct oral anticoagulant therapy reversal
    Michael P. Gulseth · 2016 · American Journal of Health-System Pharmacy
40. Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect
    Kunihiko Nagakari, Mari Emmi, Toshiaki Iba · 2016 · Clinical and Applied Thrombosis/Hemostasis
41. Apixaban and Rivaroxaban Anti-Xa Level Monitoring Versus Standard Monitoring in Hospitalized Patients With Acute Kidney Injury
    William F. Towers, Steffany N. Nguyen, Melanie C. Ruegger, Eric Salazar, Kevin R. Donahue · 2021 · Annals of Pharmacotherapy
42. A Systems Pharmacology Model for Predicting Effects of Factor Xa Inhibitors in Healthy Subjects: Assessment of Pharmacokinetics and Binding Kinetics
    X Zhou, DRH Huntjens, RAHJ Gilissen · 2015 · CPT Pharmacometrics & Systems Pharmacology
43. Dosing considerations in the use of the direct oral anticoagulants in the antiphospholipid syndrome
    Jill R. Schofield, Kathryn Louise Hassell · 2017 · Journal of Clinical Pharmacy and Therapeutics
44. Direct oral anticoagulants in patients with severe inherited thrombophilia: a single-center cohort study
    Joanna Żuk, Elżbieta Papuga-Szela, Lech Zaręba, Anetta Undas · 2020 · International Journal of Hematology
45. Evaluation of Anti-Xa Apixaban and Rivaroxaban Levels With Respect to Known Doses in Relation to Major Bleeding Events
    Steffany N. Nguyen, Melanie C. Ruegger, Eric Salazar, Diane Dreucean, Alexandra W. Tatara, Kevin R. Donahue · 2021 · Journal of Pharmacy Practice
46. Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3)
    Giancarlo Agnelli, Alexander S. Gallus, Michael Rud Lassen, Martin H. Prins, Ronny W. Renfurm, Makoto Kashiwa, Alexander G.G. Turpie, Bengt I. Eriksson · 2013 · Thrombosis and Haemostasis
47. Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation
    John W. Eikelboom, Jeffrey Ian Weitz · 2015 · Thrombosis and Haemostasis
48. Implications of apixaban for dental treatments
    Adrián Curto, Alberto Albaladejo · 2016 · Journal of Clinical and Experimental Dentistry
49. Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy
    Lauren J. Andrews, Scott T. Benken, Xing Tan, Eric Wenzler · 2021 · BMC Nephrology
50. Pharmacogenetics of Direct Oral Anticoagulants
    Natalia Alekseevna Shnayder, Марина Михайловна Петрова, Бочанова Елена Николаевна, O. V. Zimnitskaya, A. V. Savinova, Е. А. Пожиленкова, Regina Nasyrova · 2021 · IntechOpen eBooks
51. An Update on Anticoagulation in Atrial Fibrillation
    John V. Amerena, Daryl Ridley · 2017 · Heart Lung and Circulation
52. An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms
    Annette von Drygalski, Vikas Bhat, Andrew J. Gale, Patricia M. Averell, Thomas J. Cramer, Darlene J. Elias, John H. Griffin, Laurent O. Mosnier · 2020 · Blood Advances
53. Evaluation of global laboratory methods and establishing on‐therapy ranges for monitoring apixaban and rivaroxaban: Experience at a single institution
    Soon Ho Park, Yiel‐Hea Seo, Pil‐Whan Park, Kyung‐Hee Kim, Ja Young Seo, Hwan Tae Lee, Woo‐Jae Kwoun, Jeong Yeal Ahn · 2019 · Journal of Clinical Laboratory Analysis
54. Development of Interstitial Lung Disease after Initiation of Apixaban Anticoagulation Therapy
    Shinya Tomari, Kazunari Homma, Teruo Noguchi, Takeshi Aiba, Takayuki Matsuki, Riéko Suzuki, Masatoshi Koga, Masao Takigami, Hiroshi Tagawa, Taisuke Hashimoto et al. · 2016 · Journal of Stroke and Cerebrovascular Diseases
55. A Case of a Reversible Neurologic Adverse Reaction to Apixaban Confirmed by Re-Challenge
    James A. Josyln, Furqan Habib Khattak, Stephen A. Geraci · 2018 · Journal of Clinical Medicine Research
56. Effectiveness and safety of non-vitamin K antagonist oral anticoagulant in the treatment of patients with morbid obesity or high body weight with venous thromboembolism: A meta-analysis
    Hongxia Zhang, Hua Xie, Xiaoyan Wang, Zonghong Zhu, Feng Duan · 2023 · Medicine
57. Apixaban pharmacodynamic activity in umbilical cord, paediatric, and adult plasma
    Robert J. Yetman, Yu Chen Barrett, Zhaoqing Wang, Robert Adamczyk, Jessie J.J. Wang, Eduardo Ramacciotti, Charles E. Frost · 2017 · Thrombosis and Haemostasis
58. Self‐poisoning with 60 tablets of Apixaban, a pharmacokinetics case report
    Bénédicte Franck, Sylvain Dulaurent, Souleiman El Balkhi, Caroline Monchaud, Nicolas Picard, Sylvain Couderc, Pierre Marquet, Franck Saint‐Marcoux, Jean‐Baptiste Woillard · 2018 · British Journal of Clinical Pharmacology
59. Outcomes Associated With 4‐Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients
    Emily A. Highsmith, Celia Morton, Sara Varnado, Kevin R. Donahue, Suraj Sulhan, Annette D. Lista · 2020 · The Journal of Clinical Pharmacology
60. Pharmacokinetics of Apixaban Among Peritoneal Dialysis Patients
    Winston Wing‐Shing Fung, Phyllis Mei‐Shan Cheng, Jack Kit‐Chung Ng, Gordon Chun‐Kau Chan, Kai Ming Chow, Philip Kam‐Tao Li, Cheuk‐Chun Szeto · 2023 · Kidney Medicine
61. Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants
    Sarah Lessire, Anne-Sophie Dincq, Jonathan Douxfils, Bérangère Devalet, Jean‐Baptiste Nicolas, Spinewine Anne, Anne‐Sophie Larock, Dogné Jean-Michel, Maximilien J. Gourdin, François Mullier · 2014 · BioMed Research International
62. Apixaban and oral implications
    Mónica Paula López-Galindo, José Vicente Bagán Sebastián · 2015 · Journal of Clinical and Experimental Dentistry
63. Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion
    Bruce A. Warden, John MacKay, Melika Jafari, Alana M Willman, Eric C. Stecker · 2018 · Journal of the American Heart Association
64. Determination of Apixaban Levels in Human Plasma by a High-Throughput Liquid Chromatographic Tandem Mass Spectrometry Assay / Determinarea rapidă a apixabanului în plasma umană prin cromatografie de lichide de înaltă performanță cuplată cu spectrometrie de masă în tandem
    Ioan Ţilea, Daniela‐Saveta Popa, Timea Szakács Xantus, Daniela Petruta Primejdie, Grigorescu Bianca, Brînduşa Ţilea, Andreea Elena Bocicor, Andreea Varga · 2015 · Revista română de medicină de laborator
65. Anticoagulation and antiplatelet therapy in short bowel syndrome: A systematic review
    Carolyn Mercer, Anna Crawford, Susan Shapiro, Philip Allan, Tim Ambrose · 2024 · Intestinal failure.
66. Latest developments in anticoagulant drug discovery
    Erasmia Broussalis, Wallner Anna, Eugen Trinka, Johannes Sebastian Mutzenbach, Monika Killer‐Oberpfalzer · 2014 · Drug Discovery Today
67. Anticoagulant Reversal and Anesthetic Considerations
    Joseph S. Meltzer, Joseph R. Guenzer · 2017 · Anesthesiology Clinics
68. Population Pharmacokinetics and Pharmacodynamics of Apixaban Linking Its Plasma Concentration to Intrinsic Activated Coagulation Factor X Activity in Japanese Patients with Atrial Fibrillation
    Satoshi Ueshima, Daiki Hira, Chiho Tomitsuka, Miki Nomura, Yuuma Kimura, Takuya Yamane, Yohei Tabuchi, Tomoya Ozawa, Hideki Itoh, Minoru Horie et al. · 2019 · The AAPS Journal
69. New oral anticoagulants: an approach in older people
    Beth La Brooy, Prahlad W. Ho · 2015 · Journal of Pharmacy Practice and Research
70. Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date
    Vladimir Trkulja · 2016 · Drug Healthcare and Patient Safety
71. Newer Oral Anticoagulants: Stroke Prevention and Pitfalls
    Anand V Patel, Richard Goddeau, Nils Henninger · 2016 · The Open Cardiovascular Medicine Journal
72. Steuerung der NOAK-Gabe bei invasiven oder operativen Interventionen
    Michael Buerke, Hans-Martin Hoffmeister · 2017 · Medizinische Klinik - Intensivmedizin und Notfallmedizin
73. Complete investigations (autopsy, toxicology, and histology) in a death due to apixaban overdose
    Pascal Kintz, Charlotte Allain, Laetitia Oertel, Emilie Feisthauer, Alice Ameline, Jean‐Sébastien Raul · 2023 · International Journal of Legal Medicine
74. Plasma apixaban concentrations and thrombin generation assay parameters in response to dose reduction for atrial fibrillation
    Muhan Yeo, So‐Ryoung Lee, Eue‐Keun Choi, JungMin Choi, Kyung‐Yeon Lee, Hyo‐Jeong Ahn, Soonil Kwon, Hyoung‐Seob Park, Hyun Kyung Kim, Seil Oh et al. · 2024 · British Journal of Clinical Pharmacology
75. Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series
    Celia Morton, Annette D. Lista, Nicholas D. Jakowenko, Eric Salazar, Kevin R. Donahue · 2021 · Journal of Thrombosis and Thrombolysis
76. Frailty as a Marker for the Plasma Concentrations of Direct Oral Anticoagulants in Older Patients: Results of an Exploratory Study
    Annette Eidam, Julian Marji, Petra Benzinger, Kathrin Isabelle Foerster, Jürgen Burhenne, David Czock, Felicitas Stoll, Antje Blank, Gerd Mikus, Walter E. Haefeli et al. · 2023 · Drugs & Aging
77. Physiologically based pharmacokinetic modeling of apixaban to predict exposure in populations with hepatic and renal impairment and elderly populations
    Yichao Xu, Lei Zhang, Xiaofan Dou, Yongze Dong, Xiangchai Guo · 2023 · European Journal of Clinical Pharmacology
78. Randomized, blinded, placebo‐ and positive‐controlled crossover study to determine the effect of multiple doses of apixaban on the QTc interval
    Charles E. Frost, Sunil Nepal, Wonkyung Byon, Kenneth Todd Moore, Richard A. Reeves, Rebecca A. Boyd, Frank P. LaCreta · 2014 · The Journal of Clinical Pharmacology
79. Horizontal vs. vertical dose reduction of direct oral anticoagulants in patients with non-valvular atrial fibrillation: definition and implications for practice
    Andrea Rubboli · 2019 · European Journal of Internal Medicine
80. International Normalized Ratio as a Screening Test for Assessment of Anticoagulant Activity for Patients Treated With Rivaroxaban or Apixaban: A Pilot Study
    Fanny Ofek, Dana Barchel, Nofar Perets, Tomer Ziv‐Baran, Ahmad Mahajna, Talia Filipovich‐Rimon, Osnat Garach‐Jehoshua, Maya Berlin, Matitiahu Berkovitch · 2019 · Frontiers in Pharmacology
81. Apixaban in low‐weight patients with cancer‐associated thrombosis: A cross sectional study of drug levels
    Verónica Bravo Villa, J. García Romero, Eunice Rojas‐Zaldivar, Martha Cervantes, María del Rosario Villa‐Márquez, Patricia Baz, Gabriela Nora Cesarman-Maus · 2021 · Research and Practice in Thrombosis and Haemostasis
82. Apixaban-induced liver injury
    Salvador Machlab, Mireia Miquel, Mercedes Vergara, Maria Rosa Escoda, Meritxell Casas · 2018 · Revista Española de Enfermedades Digestivas
83. Can a Single Measurement of Apixaban Levels Identify Patients at Risk of Overexposure? A Prospective Cohort Study
    Tim A.C. de Vries, Jack Hirsh, Vinai C. Bhagirath, Jeffrey S. Ginsberg, Ron Pisters, Martin E W Hemels, Joris R. de Groot, John W. Eikelboom, Noel Chan · 2022 · TH Open
84. Direct oral to parenteral anticoagulant transitions: Role of factor Xa inhibitor‐specific anti‐ X a concentrations
    Corey V. Dinunno, Chelsea N. Lopez, Luma Succar, Duc T. Nguyen, Edward A. Graviss, Eric Salazar, Kevin R. Donahue · 2022 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
85. Moving Beyond Warfarin—Are We Ready?: A Review of the Efficacy and Safety of Novel Anticoagulant Agents Compared to Warfarin for the Management of Atrial Fibrillation in Older Adults
    Kelechi C. Ogbonna, Kalin M. Clifford · 2013 · Journal of Gerontological Nursing
86. Descriptive analysis evaluating the use of direct oral anticoagulation therapy in heart and lung transplant recipients
    Eric D. Rubido, Megan H. Cooper, Kevin R. Donahue, Jill C. Krisl · 2022 · Clinical Transplantation
87. Evaluating the efficacy and safety of apixaban, a new oral anticoagulant, using Bayesian meta-analysis
    Lorenzo Villa Zapata, Daniel C. Malone, Daniel Ross · 2013 · International Journal of Hematology
88. Measuring or Monitoring of Novel Anticoagulants: Which Laboratory Test to Request?
    Paul P. Dobesh, Kimberly J. Terry · 2013 · Current Emergency and Hospital Medicine Reports
89. Apixaban Interacts with Haemoglobin: Effects on Its Plasma Levels
    Monica Sacco, Stefano Lancellotti, Federico Berruti, Alessandro Arcovito, Andrea Bellelli, Tiziana Ricciardelli, Ida Autiero, Luigi Cavallo, Romina Oliva, Raimondo DE CRISTOFARO · 2018 · Thrombosis and Haemostasis
90. Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation
    Qinmei Xiong, Yee Cheng Lau, Gregory Y.H. Lip · 2015 · Expert Opinion on Drug Metabolism & Toxicology
91. Anticoagulant activity of direct factor Xa inhibitors as a tool to ensure the effectiveness and safety of drugs intake
    Т. В. Вавилова · 2019 · Kardiologiia
92. Pharmacokinetics and Pharmacogenetics of Apixaban
    A. V. Savinova, Марина Михайловна Петрова, Natalia Alekseevna Shnayder, Бочанова Елена Николаевна, R. F. Nasyrova · 2020 · Rational Pharmacotherapy in Cardiology
93. Altered plasma levels of apixaban in major gastrointestinal tract surgery: A case report and review of the literature
    Giammarco Baiardi, Alessia Cafaro, Manuela Stella, Michela Cameran Caviglia, Maria Gabriella Poeta, Giuliana Cangemi, Francesca Mattioli · 2023 · Clinical Biochemistry
94. A practical synthesis for the key intermediate of apixaban
    Wenwen Dong, Tengfei Gong, Chaoyang Liu, Jia Lin, Qiang Jia, Changhu Chu · 2023 · Monatshefte für Chemie - Chemical Monthly
95. Monitoring target-specific oral anticoagulants
    Barbara A. Konkle · 2014 · Hematology
96. Clinical controversies in the treatment of cancer-associated venous thromboembolism
    Victoria R. Nachar, Allison J. Schepers · 2021 · Journal of Oncology Pharmacy Practice
97. A liquid chromatography-tandem mass spectrometry method for the determination of apixaban in human plasma and its application to pharmacokinetics studies in the Indian population
    Khurshid Shaikh, Ashish Mungantiwar, Supriya Halde, Nancy S. Pandita · 2021 · Analytical Methods
98. Apixaban in a porcine model of mechanical valve thrombosis in pulmonary position—a pilot study
    Lucas Van Hoof, Isabelle Truyers, Hadewych Van Hauwermeiren, Bram Nachtergaele, Tom Langenaeken, Marc G Jacquemin, Filip Rega, Peter B. Verhamme, Bart Meuris · 2022 · Interactive Cardiovascular and Thoracic Surgery
99. What you need to know about migraine in Hughes syndrome patients
    Jill R. Schofield, KL Hassell · 2023 · Lupus
100. Risk of Major Bleeding Associated with Concomitant Direct-Acting Oral Anticoagulant and Clopidogrel Use: A Retrospective Cohort Study
     Yoseob Joseph Hwang, Hsien‐Yen Chang, Thomas Stephen Metkus, Kathleen M. Andersen, Sonal Singh, G. Caleb Alexander, Hemalkumar B. Mehta · 2023 · Drug Safety